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Abstract
Background: Cytoplasmic lipid-droplets are common inclusions of eukaryotic cells. Lipid-droplet binding thalidomide 
analogs (2,6-dialkylphenyl-4/5-amino-substituted-5,6,7-trifluorophthalimides) with potent anticancer activities were 
synthesized.
Results: Cytotoxicity was detected in different cell lines including melanoma, leukemia, hepatocellular carcinoma, 
glioblastoma at micromolar concentrations. The synthesized analogs are non-toxic to adult animals up to 1 g/kg but 
are teratogenic to zebrafish embryos at micromolar concentrations with defects in the developing muscle. Treatment 
of tumor cells resulted in calcium release from the endoplasmic reticulum (ER), induction of reactive oxygen species 
(ROS), ER stress and cell death. Antioxidants could partially, while an intracellular calcium chelator almost completely 
diminish ROS production. Exogenous docosahexaenoic acid or eicosapentaenoic acid induced calcium release and 
ROS generation, and synergized with the analogs in vitro, while oleic acid had no such an effect. Gene expression 
analysis confirmed the induction of ER stress-mediated apoptosis pathway components, such as GADD153, ATF3, 
Luman/CREB3 and the ER-associated degradation-related HERPUD1 genes. Tumor suppressors, P53, LATS2 and ING3 
were also up-regulated in various cell lines after drug treatment. Amino-phthalimides down-regulated the expression 
of CCL2, which is implicated in tumor metastasis and angiogenesis.
Conclusions: Because of the anticancer, anti-angiogenic action and the wide range of applicability of the 
immunomodulatory drugs, including thalidomide analogs, lipid droplet-binding members of this family could 
represent a new class of agents by affecting ER-membrane integrity and perturbations of ER homeostasis.
Background
Cytoplasmic lipid-droplets (LDs) are common inclusions
of eukaryotic cells. Little is known about the composition
or physiological role of LDs, however growing number of
evidences imply that LDs are not solely static inclusions
for storage of excess lipid, but they are dynamic and func-
tionally active [1-4]. Although LD biogenesis is not well
understood, it is assumed that the LDs form within the
two leaflets of the ER membrane to function as lipid stor-
age sites [5]. LDs are active inclusions with essential roles
in membrane trafficking, cell signaling and distributing
specific lipids and proteins [6,7]. LDs are also sites for
cytokine storage in inflammatory leukocytes, suggesting
that LDs function as inducible intracellular platforms for
spatial segregation and organization of signaling leading
to inflammatory mediator secretion during inflammation
[8]. Under hypoxic conditions or when free fatty acid
overload occurs (exogenously from the serum or due to
intracellular alterations e.g. when beta-oxidation is
blocked) the number of LDs increases [9]. It was shown
that LD accumulation occurs in vivo at prenecrotic can-
cer tissues [10] and border zones of experimental myo-
cardial infarcts [11], therefore LDs can be in vivo markers
of cancer and ischemic insults [12]. When the amount,
distribution and the rate of formation of LDs are altered
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by small molecules, membrane transport and lipid
h o m e o s t a s i s  c o u l d  b e  i m p a i r e d  i n  c a n c e r  c e l l s .  T h u s ,
tumor cells are much more dependent upon fatty acid
removal than normal cells, where beta-oxidation is not
affected by oxygen depletion. Imbalance in lipid homeo-
stasis can finally lead to membrane disruption and activa-
tion of lipoapoptosis [13]. As LDs are formed in the ER
we hypothesized that specific LD-binding drugs could
interfere with LD homeostasis and ER-membrane integ-
rity and could trigger apoptosis through ER stress.
We synthesized novel LD-binding thalidomide analogs
(amino-substituted-trifluoro-phthalimides), with strong
inherent blue fluorescence, which localize specifically to
LDs and at higher concentrations to ER. They possess
potent anticancer activities in vitro in a variety of cell
lines and they, like non-fluorescent immunomodulatory
drugs (IMiDs) and thalidomide analogs such as Revlimid
(lenalidomide), Actimid and CPS49 [14,15], induce reac-
tive oxygen species (ROS) originating in the ER [16].
Thalidomide is best known as a major teratogen that
caused birth defects (stunted limb growth) in up to
12,000 children in the 1960 s. Despite its tragic initial
experience, thalidomide has become the subject of major
interest because of its wide range of biological activities
and newly demonstrated clinical value in infectious dis-
ease and cancer [17,18]. Thalidomide and their analogs
are currently being used experimentally to treat various
cancers and inflammatory diseases (for review see
[14,17,18]). Because the use of thalidomide is limited by
toxicity and limited efficacy, novel and more potent
derivatives are under development [18-21].
Here, we studied the interacting protein targets of
amino-substituted-trifluoro-phthalimides and their
effects on calcium-release, ROS production, ER-stress
and gene expression changes in different treated cancer
cells. We also examined whether different fatty acids
could influence the effects of our new compounds. Our
results might open novel therapeutic strategies by using
LD-binding molecules and also emphasize the impor-





fluorophthalimides (AC-177: 4-cyclopentyl-; AC-202: 5-
ethyl-; AC-1041: 4-morpholine-) were synthesized from
2,6-diisopropylphenyl-4-5,6,7-tetrafluorophthalimide
[21] and pentylamine, ethylamine or morpholine (Sigma,
USA) in chloroform at reflux temperature for 6 h. The 4-
(e.g. AC-177 or AC-1041) and 5- (e.g. AC-202) isomers
were separated in silica column chromatography by using
hexane:chloroform (1:1) eluent. The purity of the com-
pounds was assessed by HPLC. The structure of the com-
pounds was confirmed by NMR or X-ray diffraction (data




dione were synthesized according to US 20040077685A1
patent. Lenalidomide (cc5013) was purchased from Hal-
lochem (Chongqing, China), thalidomide and other
chemicals from Sigma (St. Louis, MO, USA).
Intracellular localization
HepG2 and HT168 cells were grown on cover-slips,
washed in phosphate-buffered saline (PBS), and fixed for
10 min at room temperature with 4 % p-formaldehyde in
PBS supplemented with 5 mM each of MgCl2 and EGTA.
After washing with PME, LDs were first stained with oil
red O for 10 min, than incubated with 10 μM AC com-
pounds in PME for 5 min and mounted in Fluoromount-
G mounting solution (Southern Biotechnology Associ-
ates, Birmingham, AL). HT168 cells were cultured in
glass bottom culture dishes (MatTek Corporation, Ash-
land, MA). ER was labeled with BODIPY-FL-glibencl-
amid according to the ER-Tracker Green (Invitrogen,
Carlsbad, CA) manufacturer's protocol in live cells. After
staining we replaced the solution with fresh Hank's Bal-
anced Salt Solution with calcium and magnesium con-
taining 5 μM AC-202 or AC-1041 and after 5 min the
cells were visualized using fluorescence microscope.
Fluorescence microscopy was performed using a confo-
cal microscope (Olympus Fluoview FV1000 Confocal
Laser Scanning Microscope) equipped with 20× (N.A
0.75) and 40× oil (N.A 1.3) objectives. We applied a 543
nm laser with Alexa Fluor 546 configuration for detection
of oil red O staining of oil bodies and 405 nm laser with
DAPI configuration for detection of AC compounds.
In vivo staining with AC-202 was performed on SCID
mouse after 28 days intra-spleen inoculation of 106
HT168 cells. 2 h after single oral administration of 200
mg/kg AC-202, mice were sacrificed and livers were fro-
zen and sectioned for confocal microscopy.
Cell culture studies
HepG2 (hepatocarcinoma) and MCF7 (breast adenocar-
cinoma), U87 (glioblastoma), HT168 (melanoma), K562,
HL60 (myeloid leukemia), U266 (multiple myeloma) cells
were obtained from the ATCC collection and maintained
in suggested medium in a humidified atmosphere of 95%
air and 5% CO2. For cytotoxicity assays, 10.000 cells were
seeded into one well of 96-well cell culture plates. Effects
of the analogs were recorded 24-72 h after treatment.
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium) assay was applied to drug treated and control (0.2%
DMSO) cells at different concentrations with CellTiterPuskás et al. Lipids in Health and Disease 2010, 9:56
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96® AQueous Assay (Promega, Madison, WI) according to
the manufacturer's protocol.
For gene expression analysis cell lines (K562, HL60,
U266, HT168, U87, HepG2 and MCF7) (seeded at a den-
sity of 5 × 104 cells/cm2 into 100 mm cell culture dishes)
were treated with different drugs at different concentra-
tions (thalidomide: 100 μM, cc5012: 20 μM, CPS48: 20
μM, TFFi: 10 μM, CPS49: 10 μM and AC-1041: 10 μM)
for 4 h. Quadruplicate samples for each compound and
their respective controls were collected.
Intracellular calcium ion determination
Cultured K562 cells were attached, using Cell-Tak, to a
coverslip (ø 24 mm) forming the base of a perfusion
chamber mounted on an Olympus microscope (Olym-
pus, Budapest, Hungary). The K562 cells were bathed in
standard Hepes solution at 37°C and loaded with the
Ca2+-sensitive fluorescent dye FURA 2-AM (4-5 μmol/L)
for 30 min. After loading, the cells were continuously per-
fused with solutions at a rate of 4-5 mL/min. Changes in
intracellular Ca2+ concentration ([Ca2+]i) were measured
using a CellR imaging system (Olympus). Each cell was
excited with light at wavelengths of 340 nm and 380 nm,
and the 380/340 fluorescence emission ratio was mea-
sured at 510 nm. One [Ca2+]i measurement was obtained
per second. The standard Hepes-buffered solution con-
tained 130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM
MgCl2, 10 mM D-glucose and 10 mM Na-Hepes. Cells
were loaded with AC-1041 for 2 min.
ROS determinations
ROS generation was determined by the increase in
DCFDA (2',7'-dichlorodihydrofluorescein diacetate,
Sigma) fluorescence after drug stimulation. HT168 cells
were washed, resuspended in 1% bovine serum albumin
i n  H a n k s  b u f f e r e d  s a l i n e  s o l u t i o n  ( B S A - H B S S )  a t  1 0 6
cells/mL and maintained at 37°C for analysis. Cells were
treated with the indicated drugs (AC-177, CPS49) and
with or without different antioxidants (rotenone: 0.1 μM;
gluthatione (GSH): 0.4 mM; N-acetyl cysteine (NAC): 0.4
mM; tiron: 0.5 mM; epigallocatechin (EPG): 0.1 mM;
buthylsulfoxide (BSO): 0.1 mM; catalase: 100 U; vitamin
C: 50 μM), fatty acid (EPA: 50 μM) and BAPTA-AM (50
μM). DCFDA was added 60 min prior to harvest, at 2 μM
final concentration. All the other parameters and calcula-
tions were done as described before [16].
Toxicity and teratogenic analysis
Acute toxicology studies were performed on two-
months-old male CD/1 mice and Wistar female rats that
were kept in a conventional animal house and received
conventional food pellets and tap water ad libitum
throughout the experiments. One dose of AC-202 or AC-
1041 at 800 mg/kg or 1.2 g/kg dose was orally given to 10
animals in 0.5% methylhydroxyl-cellulose suspension by
gavage (0.45 ml for mice and 2 ml for rats). Additionally,
one dose of 2 g/kg of AC-202 was orally given to 10 rats.
Toxic effects were recorded for 2 weeks. All animal exper-
iments were performed respecting institutional animal
welfare guidelines.
Teratogenic analysis was performed on zebrafish
embryos [22]. AC-202, AC-1041 and thalidomide were
dissolved in DMSO at final concentration of 1 mM. One
in 1000 and 1/200 dilutions were applied into the water.
Malformations and death were recorded at 24, 48 and 72
hpf (hours post fertilization).
Gene expression analysis
Total RNA was purified from drug treated and control
(0.2% DMSO) cells at various concentrations with Accu-
Prep™ RNA purification kit (Bioneer, Daeleon, Korea)
according to the manufacturers' protocol, except that
DNase I treatment was incorporated.
For DNA-microarray analysis human microarrays of 8-
plex format from Agilent Technologies (Palo Alto, CA,
USA) with 14,833 probes were used. 1 μg of total RNA
from AC-1041-treated and control K562 cells were
amplified with the AminoAllyl MessageAmp™ II aRNA
Amplification Kit (Ambion, Austin, Texas), and labeled
with either Cy5 or Cy3 dyes according to the manufac-
turer's instructions (Ambion). Each array was scanned at
543 nm (for Cy3 labeling) or at 633 nm (for Cy5 labeling)
in Agilent Scanner using the built-in XDR (Extended
Dynamic Range) function with 5 μm resolution. Output
image analysis and feature extraction was done using Fea-
ture Extraction software of Agilent. DNA-microarray
study was done in quadruplicates and with dye-swap pro-
tocol. The results were deposited at GEO (Gene Expres-
sion Omnibus) database with an accession number:
GSE14945.
For quantitative real-time PCR (QRT-PCR) total RNA
(2 μg) was converted into cDNA with the High-Capacity
cDNA Archive Kit (Applied Biosystems, Foster City, CA)
and without purification the mixture was applied to
QRT-PCR analysis. QRT-PCR was performed on a
RotorGene 3000 instrument (Corbett Research, Sydney,
Australia) with gene-specific primers http://www.brc.hu/
pub/LHD/LHDPrimers.xls and SybrGreen protocol [23].
Curves were analyzed by using dynamic tube and slope
correction methods with ignoring data from cycles close
to baseline. Relative expression ratios were normalized to
the geometric mean of two housekeeping genes, ubiq-
uitin and hypoxanthin phosphoribosyltransferase.
Results
Novel thalidomide analogs
Novel thalidomide analogs, 2,6-diisopropylphenyl-4/5-
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177: 4-pentyl-; AC-202: 5-ethyl-; AC-1041: 4-morpho-
line-) were synthesized from 2,6-diisopropylphenyl-4-
5,6,7-tetrafluorophthalimide [24] (see structures in Fig.
1). Several primary and secondary amine compounds
including heterocyclic structures were chemically reacted
and novel thalidomide derivatives were prepared and
characterized (unpublished results). All possessed a
strong blue fluorescence (e.g.: AC-202: Λex: 377 nm, Λem:
481 nm), that made cell/animal analyses more conve-
nient.
Intracellular localization
Fluorescence confocal microscopic study was undertaken
to determine the subcellular localization of the new thali-
domide analogs in human cells. AC compounds exhibited
specific staining of LDs at 5 μM concentration assessed
by complete co-localization with oil red O, an LD-specific
dye in HT168 human melanoma cells (for AC-202 see Fig.
2a-c). When higher concentrations and higher laser
power were applied, AC-202 also showed ER localization
(Fig. 2d-f). Complete LD co-localization for all AC com-
pounds listed in the Materials and Methods section were
reproducible on other cell lines (MCF7, HepG2, A549,
K562, HL60, U87, U266), as well (data not shown).
In vivo staining of pre-necrotic, necrotic tumor tissues
(human HT168 melanoma cells) in SCID mouse liver
could be seen after single oral administration of 200 mg/
kg AC-202 (Fig. 2g-i). Lipid droplets were accumulated in
tumor tissues and were stained by the inherent fluores-
cence of the analog AC-202, while normal liver tissues
lack LDs and therefore, had much less fluorescent signals.
In vitro effects on cancer cells
Amino-trifluoro-phthalimides exerted potent anticancer
activities in vitro. Cytotoxicity was evident after 4-16 h
exposure depending on the cell type (data not shown). In
human erythroleukemia cells (K562), which showed sig-
nificant resistance against several thalidomide analogs
[15], amino-trifluoro-phthalimides were effective below
10 μM concentration (for AC-1041 see Fig. 3).
Figure 2 Intracellular localization of AC-202. HT168 human mela-
noma cells were double-stained with the blue fluorescent AC-202 (a. 5 
μM; d. 20 μM), lipid droplet-specific dye (oil red O) (b), and endoplasmic 
reticulum-specific dye (ER-Tracker™ Green) (e). Purple color derives 
from co-localization of oil red O and AC-202 (c). Cyan color derives 
from co-localization of ER-Tracker™ and AC-202 (f). Pictures d-f were re-
corded with higher laser power. In vivo staining of lipid droplets in 
prenecrotic cancer tissues (HT168 xenograft) in liver of SCID mouse by 
AC-202 (g-i). "C" denotes for cancer tissue, "N" for normal. Cancer and 
normal cells are separated by a dashed line.
Figure 3 Cytotoxic activity of 10 μM AC-1041 on human erythro-
leukemia cells. Pictures were recorded from the same area after 1 h 
and 24 h treatment. Cont: control cell lines treated with vehicle (0.1% 
DMSO). Cell divisions between 4 h-24 h are labeled with circles.
Figure 1 Chemical structure of thalidomide, lenalidomide, CPS-
49, and trifluoro-amino-phthalimides: AC-177, AC-202 and AC-
1041.Puskás et al. Lipids in Health and Disease 2010, 9:56
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Cytotoxicity could be observed in all cell lines analyzed:
in leukemia (K562, HL60), myeloma (U266), glioblastoma
(U87), melanoma (HT168), breast cancer (MCF7) and
hepatocellular carcinoma (HepG2). The most effective
compound was AC-1041 with IC50 values of 5-15 μM.
The most sensitive cell lines were the leukemia cells (5
μM), while melanoma, hepatocellular carcinoma and
glioblastoma cell lines were the most resistant (15 μM).
Elevation of intracellular calcium ion and ROS
In human erythroleukemia cells (K562) LD-binding
amino-trifluoro-phthalimides induced intracellular cal-
cium ion release from the ER (see Fig. 4 for induction by
AC-1041 at 10 μM concentration) as detected by mea-
surement of the Ca2+-sensitive fluorescent dye FURA 2-
AM for 30 min after drug administration. AC-1041
evoked a large initial peak in [Ca2+]i followed by a sus-
tained plateau in 25% of the cells, however, in 14% of the
cells AC-1041 evoked repetitive [Ca2+]i transients. 61% of
the cells did not (or very slightly) respond.
To investigate whether amino-trifluoro-phthalimides
exert a pro-oxidative effect, the presence of ROS in can-
cer cells was measured after exposure of the cells to the
analogs. AC-177 and other analogs generated significant
levels of ROS in HT168 cells, while control compounds
cc5013, thalidomide and CPS49 showed only minimal
elevation compared with that of untreated HT168 cells
(for CPS49 and AC-177 ROS levels, see Fig. 5A). The
effects of different antioxidants (rotenone, GSH, NAC,
tiron, EPG, BSO, catalase and vitamin C) and polyunsatu-
rated fatty acid EPA were also recorded on ROS produc-
tion (Fig. 5A). Among the antioxidants only NAC and
tiron could diminish ROS production. Interestingly, vita-
min C and EPA raised the AC-177-induced ROS levels.
Moreover, the addition of different polyunsaturated fatty
acids (PUFAs) (EPA or DHA) in combination with AC-
177 resulted in synergistic effects on ROS production
(Fig. 5B). When oleic acid was used no such an effect
could be detected. The synergistic effect of EPA or DHA
was concentration dependent. This could be seen with
the LD-binding amino-trifluoro-phthalimides treatment,
but the effect was lacking or was more moderate for other
thalidomide analogs (for CPS49 see Fig. 5A).
To reveal the correlation of induction of intracellular
calcium ion and ROS production of the analogs we stud-
ied the effects of cell-permeable calcium chelating agent,
BAPTA-AM together with AC-177 and with PUFAs. We
found that BAPTA-AM almost completely abolished
ROS formation of AC-177 alone or with the PUFAs used
(Fig 5A).
Toxicity and teratogenicity
Acute toxicology studies were performed on CD/1 mice
and Wistar rats. AC-202 or AC-1041 was administered
orally. There were no toxic effects up-to very high con-
centrations (LD50: 1 g/kg for mouse and 1.2 g/kg for rat)
Figure 4 Representative experimental traces showing the differ-
ent effects of AC-1041 on [Ca2+]i in perfused K562 cells. Shown are 
the typical patterns of [Ca2+]i changes in the cells perfused with AC-
1041. Increase in [Ca2+]i is denoted by a change from a ''cold'' color 
(blue) to a ''warmer'' color (yellow to red). Pictures 1-4 were taken at the 
times indicated in the graph.
Figure 5 Effect of different antioxidants and EPA on AC-177-in-
duced oxidative stress in HT168 human melanoma cells (A). Stim-
ulated increase in ROS formation after treatment of HT168cells with 
AC177 (5 μM) alone or in the presence of different concentrations of 
EPA, DHA and oleate (B).Puskás et al. Lipids in Health and Disease 2010, 9:56
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for adult animals, but caused severe diarrhea and appen-
dicitis and finally death (80% mortality) in rats after 7-10
days at higher doses (2 g/kg).
AC compounds exhibited strong teratogenic effects on
zebrafish embryos at low (micromolar) concentrations as
can be seen on Fig. 6. The tail of the fish is bended and
distorted (shortened and having an "S"-shaped break at
the end) when compared to control animals. The same
distortion effects can be seen for thalidomide treated ani-
mals. At the distortion site defect in muscle formation
can be seen (in Fig. 6 arrows show distortion sites of the
treated animals).
Gene-expression changes of treated cancer cells
To further investigate the mechanisms underlying growth
inhibitory effects of amino-trifluoro-phthalimides on
cancer cells, different cell lines (K562, HL60, U266,
HT168, U87, HepG2 and MCF7) were treated with AC-
1041 at an IC50 concentration for 4 h. Using treated K562
cells a gene array analysis was performed with DNA-
m i c r o a r r a y s .  M i c r o a r r a y  d a t a  w e r e  d e p o s i t e d  a t  G E O
(Gene Expression Omnibus) database with an accession
number GSE14945. AC-1041 activated expression of a set
of genes involved in the ER stress (ATF3, DDIT3
(GADD153), HERPUD1, PP1R15A, DNAJB1, DNAJB4,
DNAJB9, FOS, FOSB, JUN, NR4A1, NR4A2, RELB,
TRIB3, LCRF). Other set of induced genes are coding for
tumor suppressor proteins (TP53, ING3, LATS2) or part
of the JNK/p38 pathway (DUSP1, DUSP8, DUSP10). A
specific marker gene of cell division, CCND1 coding for
cyclin D1 was down-regulated. Significant repression of
CCL2 (chemokine C-C motif ligand 2, or MCP-1), and
induction of SNX16 (sorting nexin 16) could be detected.
To confirm the expression of these genes QRT-PCR was
done (K562 column in Table 1). In order to assess the
effects of AC-1041 on other cell lines (HL60, U266,
HT168, U87, HepG2 and MCF7) the expression of these
genes were also studied (Table 1). While almost in all cell
lines the induction of ER stress-related genes could be
observed, changes at the mRNA level of TP53, ING3, the
DUSP family and SNX16 could be recorded only in the
sensitive cells (leukemia and myeloma) and not in other
cell lines.
Discussion
The potential to alter tumor-lipid homeostasis through
nutritional intervention was established from observa-
tions that tumors derive their fatty acids from the de novo
synthesis pathway that generates stearic and oleic acid
[25]. When the synthesis is over-balanced or when fatty
acid degradation by beta-oxidation is repressed due to
hypoxic conditions, cells direct their excess fatty acids
into intracellular lipid depots, into LDs. The lipid in these
droplets undergoes turnover via hydrolysis and re-syn-
thesis providing excellent target for affecting tumor cell
survival. Moreover LDs have recently been suggested to
represent target compartments for fatty acid scavenging
to protect cells from lipoapoptosis [26]. We hypothesized
that small molecules interacting with LDs cause imbal-
ance in lipid homeostasis resulting in membrane disrup-
tion that can finally lead to apoptosis.
We synthesized novel thalidomide analogs (2,6-dialky-
lphenyl-4/5-amino-substituted-5,6,7-trifluorophthalim-
ides) that possess bright blue fluorescence. They exerted
potent anticancer activities in vitro in different cell lines:
leukemia (K562, HL60), myeloma (U266), glioblastoma
(U87), melanoma (HT168), breast cancer (MCF7) and
hepatocellular carcinoma (HepG2). In human erythroleu-
kemia cells (K562), which showed significant resistance
against several thalidomide analogs [15], amino-trifluoro-
phthalimides were effective below 10 μM concentration.
We showed that amino-trifluoro-phthalimides localize to
LDs and at higher concentrations to ER. Moreover, oral
administration of AC-202 resulted in staining LD of met-
astatic melanoma grown in the liver of xenograft mouse
(Fig. 2g-i), suggesting not only good oral bioavailability
but also accumulation of the drugs in LDs of pre-necrotic
cancer tissues.
Based on our hypothesis regarding to ER membrane
disturbance of the LD-binding compounds and previous
findings on "redox-reactive" thalidomide analogs [15], we
studied the effects of the amino-trifluoro-phthalimides
on intracellular calcium release and ROS formation. In
K562 cells they induced intracellular calcium ion release
from the ER. They evoked a large initial peak in [Ca2+]i
followed by a sustained plateau or induced repetitive
[Ca2+]i transients (Fig. 4.). AC-177 and other analogs gen-
erated significant levels of ROS in HT168 (and K562, not
shown) cells, while control compounds cc5013, thalido-
mide and CPS-49 showed only minimal elevation com-
pared with that of untreated cells. ROS formation could
Figure 6 Teratogenic activity of AC-1041 on zebrafish embryos. 
Control embryo (CONT), Thalidomide treated (5 μM; THAL) and AC-
1041 treated (5 μM; AC-1041) embryos (b), photo was taken at 3 dpf 
(days post fertilization). Histological sections show differences in mus-
cle structure after treatment. Arrows indicates malformations.Puskás et al. Lipids in Health and Disease 2010, 9:56
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be substantially decreased by the cell-permeable calcium
chelator, BAPTA-AM, which suggests correlation
between the elevation of intracellular calcium ion con-
centration and ROS production induced by the analogs.
Different antioxidants partially diminished ROS produc-
tion, but significant reduction could be achieved only
with NAC and tiron. Interestingly, vitamin C elevated the
AC-177 induced ROS formation. The same effect could
be observed when DHA or EPA was added in combina-
tion with AC-177 (Fig. 5B). This effect could be explained
by affecting the membrane structure of the ER by polyun-
saturated fatty acids and sensitization of cells against ROS
forming agents. However, oleic acid does not display such
effect neither alone nor in combination with AC-177.
A species-specific conversion to free radical intermedi-
ates in embryonic tissue was suspected to be the main
reason for thalidomide teratogenicity [27]. Therefore, we
studied the teratogenic effects of the LD-binding thalido-
mide analogs and thalidomide as a control on zebrafish
embryos. AC-177, AC-202 and AC-1041 caused severe
morphological changes in the fish like distortion of mus-
cle development and curves in their tails at micromolar
concentrations (Fig. 6). The same pathological phenom-
ena could be detected in the case of thalidomide and
other thalidomide analogs. It is interesting that zebrafish
is sensitive to thalidomide, whereas mice and rats are not.
Similar sensitivity for aflatoxins and dimethylnitrosamine
could be found in rainbow trout to generate primary liver
carcinoma [28,29]. Besides the teratogenicity of the ana-
logs, in initial animal studies, high levels of AC-202 and
AC-1041 were well tolerated in adults, and they showed
no toxicity even at 1 g/kg dose. Therefore, the LD-binding
thalidomide analogs are ideal candidates for further in
vivo studies and possibly for entering into clinical trials
against cancer.
Thalidomide and its analogs have been discovered to
have various biological activities, such as anti-inflamma-
tory, anti-angiogenic, cyclooxygenase (COX)-inhibitory
and microtubule-perturbing activities [24,30-32]. How-
ever, there are only limited numbers of studies revealing
the mechanisms of action of different analogs by using
gene expression fingerprinting or clustering of different
Table 1: Expression changes in different cells after AC-1041 treatment.
Code Acc. No. Gene product K562 HL60 U266 HT168 U87 HEPG2 MCF7
CCL2 NM_002982 Chemokine (C-C motif) 
ligand 2
0.31 0.35 0.37 n.d. 0.80 0.34 0.51
ATF3 NM_004024 Activating transcription 
factor 3
10.21 2.75 8.17 18.29 4.10 0.66 4.32
DDIT3 NM_004083 DNA-damage-inducible 
transcript 3
3.73 3.28 6.19 3.67 2.84 2.91 6.43
LCRF NM_153607 Luman/CREB3 
rercruitment factor
4.19 10.02 2.02 12.49 2.38 2.45 n.d.
DNAJB1 NM_006145 DnaJ (Hsp40) homolog B1 10.14 3.23 4.15 10.41 5.93 5.67 2.09
HERPUD1 NM_014685 ER stress-inducible, 
ubiquitin-like 1
2.76 1.76 1.02 7.63 2.57 3.81 2.03
HSPH1 NM_006644 Heat shock 105kDa/
110kDa protein 1
3.64 2.69 1.70 3.26 1.88 2.27 0.89
TP53 NM_000546 Tumor protein p53 2.37 7.62 1.07 1.31 1.01 1.05 4.02
ING3 NM_019071 Inhibitor of growth family, 
member 3
1.63 2.10 1.80 1.92 1.59 0.72 2.51
LATS2 NM_014572 LATS, large tumor 
suppressor, homolog 2
2.62 1.73 1.20 3.57 2.11 0.24 0.65
CCND1 NM_053056 Cyclin D1 0.46 1.13 1.00 0.85 1.19 2.12 1.12
DUSP1 NM_004417 Dual specificity 
phosphatase 1
3.77 1.30 5.29 0.94 1.66 0.94 1.62
DUSP8 NM_004420 Dual specificity 
phosphatase 8
9.23 5.81 7.94 1.01 2.68 1.91 1.80
DUSP10 NM_007207 Dual specificity 
phosphatase 10
2.86 2.22 2.05 0.81 1.30 1.21 3.35
SNX16 NM_022133 Sorting nexin 16 3.19 3.07 1.39 1.07 0.75 1.24 1.92
Down-regulated gene expression values (<1.80-fold) are indicated by bold, underlined numbers, induced expression values (>1.80-fold) by bold 
and italics.Puskás et al. Lipids in Health and Disease 2010, 9:56
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biological patterns. In the present study we applied DNA-
microarrays and QRT-PCR to identify early genes
affected by the analogs. AC-1041 induced the expression
of 251 genes and repressed 37 genes (data for all of the
14,833 genes examined can be seen at GEO database with
an accession number of GSE14945) in K562 cells after 4 h
treatment. Microarray results showed that a large num-
ber of genes associated with the ER stress response are
rapidly induced by AC-1041. This suggests that AC-1041-
induced apoptosis is coupled to the ER stress response.
During this response, several pro-survival and pro-apop-
totic signals are activated and, depending on the extent of
the ER stress, cells survive or when functions of the ER
are severely impaired, they undergo apoptosis [33,34].
One of the most universal components of the ER stress-
mediated apoptosis pathway is C/EBP homologous pro-
tein (CHOP), also known as GADD153 or DDIT3 [35],
which is markedly induced by AC-1041. Other induced
genes code for proteins that are part of the JNK/p38 path-
way (DUSP1, DUSP8, DUSP10) and have roles in regula-
tion of cellular stress responses [36]. Tumor suppressor
genes (TP53, ING3, LATS2) were also induced, while a
specific marker gene of cell division, CCND1 coding for
cyclin D1 was down-regulated. Interestingly, expression
of other genes that could explain multiple action of thali-
domide analogs in vivo were also changed. CCL2  was
repressed and SNX16 was induced by more than 3-fold as
a s s e s s e d  b y  Q R T - P C R .  C C L 2  i s  a  m e m b e r  o f  t h e
cytokine/chemokine superfamily and is known to pro-
mote the migration of monocytes and macrophages to
sites of inflammation and having roles in the tumorigene-
sis and metastasis of several solid tumors [37,38]. It was
also demonstrated that CCL2 acts as a direct mediator of
angiogenesis [39]. SNX16 directs the sorting of EGFR
from early endosomes to lysosomes and thus has critical
role in the termination of EGF-induced cell signaling
[40,41].
To further investigate the mechanisms underlying
growth inhibitory effects of amino-trifluoro-phthalim-
ides different cell lines (K562, HL60, U266, HT168, U87,
HepG2 and MCF7) were treated with AC-1041 at an IC50
concentration and gene expression changes were fol-
lowed for 15 key genes (Table 1). The induction of ER
stress-related genes and repression of CCL2 could be
observed in all cell lines, suggesting common mechanism
of action. Differences could be seen in case of TP53,
ING3, DUSP family and cyclin D1, which correlated with
the chemo-sensitivity of the cells.
Considering the positive effects of AC-1041 on altering
CCL2 and SNX16 expression, it is likely that these effects
(angiogenesis and tumorigenesis inhibition by CCL2
repression, and epidermal growth factor receptor down-
regulation by SNX16 induction) in addition to induction
of ER stress pathways are important and specific for the
biological effects of amino-trifluoro-phthalimides on
cancer cells.
Conclusions
Here we report, that interference with lipid homeostasis
and ER membrane integrity of LD-binding thalidomide
analogs and the subsequently induced ER stress are cru-
cial steps in the cytotoxic action of these molecules.
Additionally to this common pathway that are affected by
"redox-reactive" thalidomide analogs, repression of CCL2
and induction of SNX16 could explain the multiple thera-
peutic actions of IMiDs. Our results might open novel
therapeutic strategies for anti-cancer drug discovery and
therapy by using LD-binding molecules and also empha-
size the importance of anti-neoplastic agents that affect
vesicle transport and the homeostasis of the ER.
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